Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.14 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)
Hyperphosphatemia is a common complication of end-stage renal disease due to decreased renal phosphate excretion. The ideal range for serum phosphate levels in CKD patients is between 3.5 and 5.5 mg/dl. CKD-MBD is linked to bone disease, cardiovascular calcification and higher morbidity and mortality rates. The management of hyperphosphatemia consists of 4 main strategies: (i) restricting dietary phosphorous intake (ii) reducing its intestinal absorption (iii) phosphate remapping and (iv) treatment and prevention of renal osteodystrophy. Phosphate binder drug therapy is the cornerstone of management. But in dialysis patient an average phosphorous intake is about 1500 mg/day or 10,500 mg/week and if it has 50% of absorption rate then more than 5000 mg of excess phosphorous has to be removed by dialysis. Hence a neutral phosphate balance can’t be maintained only with conventional hemodialysis or peritoneal dialysis. Hence the 3Ds of therapy for hyperphosphatemia includes diet, dietary restrictions, and medication.
"A Review on Management of Phosphorus in Hemodialysis Patients", International Journal of Science & Engineering Development Research (www.ijrti.org), ISSN:2455-2631, Vol.7, Issue 11, page no.165 - 169, November-2022, Available :http://www.ijrti.org/papers/IJRTI2211026.pdf
Downloads:
000205119
ISSN:
2456-3315 | IMPACT FACTOR: 8.14 Calculated By Google Scholar| ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.14 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator